- Home
- FENC vs FT Comparison
FENC vs FT Comparison
Compare FENC & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FENC | FT |
|---|---|---|
| Founded | 1996 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.8M | 199.8M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | FENC | FT |
|---|---|---|
| Price | $10.49 | $8.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.50 | N/A |
| AVG Volume (30 Days) | ★ 248.3K | 32.3K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.85% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $44,642,000.00 | N/A |
| Revenue This Year | $65.12 | N/A |
| Revenue Next Year | $41.08 | N/A |
| P/E Ratio | $1,031.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.65 | $7.57 |
| 52 Week High | $11.31 | $8.35 |
Technical Indicators
Market Signals| Indicator | FENC | FT |
|---|---|---|
| Relative Strength Index (RSI) | 59.80 | 50.53 |
| Support Level | $7.40 | $8.00 |
| Resistance Level | $11.31 | $8.08 |
| Average True Range (ATR) | 0.54 | 0.07 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 61.64 | 43.48 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.